Anti-CD20 associated enterovirus meningoencephalitis: A narrative review with two illustrative cases
Multiple Sclerosis Journal – Experimental, Translational and Clinical · 2026-07 · 12 (3)
DOI: 10.1177/20552173261471722 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Multiple Sclerosis Journal – Experimental, Translational and Clinical, online erschienen am 28.07.2026. Verfasst von Kedar R Mahajan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Mellen Center for MS Treatment and Research, Department of Neurosciences, Neurologic Institute, Cleveland Clinic, Cleveland, USA. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
B-cell depleting therapies are used for MS, autoimmune disorders, renal disease and hematological malignancies but increase infection susceptibility.
Objective
To describe two cases of enterovirus meningoencephalitis in patients receiving B-cell depleting therapy and review anti-CD20-associated cases, detailing diagnosis, treatment, and outcomes.
Methods
We present two cases, one with MS and one with minimal change disease, and review 40 additional anti-CD20 cases. Demographic, clinical, laboratory, neuroimaging, treatment, and outcomes were abstracted. Neuro-QoL measures were analyzed.
Results
Our cases were diagnosed by CSF multiplex PCR and treated with IVIg; one also received methylprednisolone and pocapavir. Persistent sequelae included dysarthria, cognitive impairment, nystagmus, pain, and reduced Neuro-QoL scores. Of 42 cases, 34 were associated with rituximab and eight with ocrelizumab. CSF PCR or molecular testing detected enterovirus in 39 cases; three required alternative specimens/sites. IVIg or subcutaneous immunoglobulin (SCIg) was used in 36 cases, steroids in seven, fluoxetine in six, pocapavir in two, pleconaril in two, and ribavirin/favipiravir in one. Outcomes included recovery in 11, sequelae in 19, and death in 12.
Conclusions
Enterovirus infection in B-cell depleted patients may cause severe CNS involvement. CSF PCR aids diagnosis, though alternative specimens may be required. Early IVIg and investigational antivirals may be considered.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Mellen Center for MS Treatment and Research, Department of Neurosciences, Neurologic Institute, Cleveland Clinic, Cleveland, USA.
- Department of Neurosciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, USA.
- Department of Neurology, Neurologic Institute, Cleveland Clinic, Cleveland, USA.
- Department of Infectious Disease, Integrated Hospital Care Institute, Cleveland Clinic, Cleveland, USA.
- Diagnostic Radiology, Imaging Institute, Cleveland Clinic, Cleveland, USA.
ORCID-Profile: Kedar R Mahajan, Mary Alissa Willis, Robert Bermel, Robert J Fox
Zitieren
APA
Mahajan, K. R., Bittner, F., Willis, M. A., Isada, C., Bermel, R., Fox, R. J., Lee, J., & Kunchok, A. (2026). Anti-CD20 associated enterovirus meningoencephalitis: A narrative review with two illustrative cases. Multiple Sclerosis Journal – Experimental, Translational and Clinical, 12(3). https://doi.org/10.1177/20552173261471722
Vancouver
Mahajan KR, Bittner F, Willis MA, Isada C, Bermel R, Fox RJ, et al. Anti-CD20 associated enterovirus meningoencephalitis: A narrative review with two illustrative cases. Multiple Sclerosis Journal – Experimental, Translational and Clinical. 2026;12(3). doi:10.1177/20552173261471722
BibTeX
@article{Mahajan2026,
author = {Mahajan, Kedar R and Bittner, Frank and Willis, Mary Alissa and Isada, Carlos and Bermel, Robert and Fox, Robert J and Lee, Jonathan and Kunchok, Amy},
title = {Anti-CD20 associated enterovirus meningoencephalitis: A narrative review with two illustrative cases},
journal = {Multiple Sclerosis Journal – Experimental, Translational and Clinical},
year = {2026},
volume = {12},
number = {3},
doi = {10.1177/20552173261471722}
}
EUVIMED